Marina Parra-Robert

Dr. Marina Parra-Robert


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
MPMarina Parra-Robert
Marina Parra-Robert
ECEudald Casals
Eudald Casals
NMNuria Massana-Martinell
Nuria Massana-Martinell
MZMuling Zeng
Muling Zeng
MPMeritxell Perramón
Meritxell Perramón
GCGregori Casals
Gregori Casals
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipids. Antisteatotic effects of cerium oxide nanoparticles (CeO2NPs) have recently been shown in animal models of liver disease. However, it is unclear whether the activity of CeO2NPs is related solely to the decrease in oxidative stress or, in addition, they directly decrease liver fatty acid accumulation. To address this question, in this work, we used an in vitro model of hepatocellular steatosis, exposing HepG2 cells to oleic and palmitic acid. Cell uptake of CeO2NPs and their effect on oxidative stress and viability of hepatic cells cultured with H2O2 were also evaluated. Results show that CeO2NPs were uptaken by HepG2 cells and reduced oxidative stress and improved cell viability. Treatment with oleic and palmitic acid increased lipogenesis and the content of different fatty acids. CeO2NPs reduced palmitic and stearic acid and most fatty acids consisting of more than 18 carbon atoms. These effects were associated with significant changes in elongase and desaturase activity. In conclusion, CeO2NPs directly protected HepG2 cells from cell injury in oxidative stress conditions and reduced fatty acid content in steatotic conditions by inducing specific changes in fatty acid metabolism, thus showing potential in the treatment of NAFLD.

Verified
Journal Article
Open access
PDF file
RWRobin Wijngaard
Robin Wijngaard
MPMeritxell Perramón
Meritxell Perramón
MPMarina Parra-Robert
Marina Parra-Robert
SHSusana Hidalgo
Susana Hidalgo
GBGina Butrico
Gina Butrico
GCGregori Casals
Gregori Casals
The metabolic ratios lactate/pyruvate and β-hydroxybutyrate/acetoacetate are considered valuable tools to evaluate the in vivo redox cellular state by estimating the free NAD+/NADH in cytoplasm and mitochondria, respectively. The aim of the current study was to validate a gas-chromatography mass spectrometry method for simultaneous determination of the four metabolites in plasma and liver tissue. The procedure included an o-phenylenediamine microwave-assisted derivatization, followed by liquid-liquid extraction with ethyl acetate and silylation with bis(trimethylsilyl)trifluoroacetamide:trimethylchlorosilane 99:1. The calibration curves presented acceptable linearity, with a limit of quantification of 0.001 mM for pyruvate, β-hydroxybutyrate and acetoacetate and of 0.01 mM for lactate. The intra-day and inter-day accuracy and precision were within the European Medicines Agency’s Guideline specifications. No significant differences were observed in the slope coefficient of three-point standard metabolite-spiked curves in plasma or liver and water, and acceptable recoveries were obtained in the metabolite-spiked samples. Applicability of the method was tested in precision-cut liver rat slices and also in HepG2 cells incubated under different experimental conditions challenging the redox state. In conclusion, the validated method presented good sensitivity, specificity and reproducibility in the quantification of lactate/pyruvate and β-hydroxybutyrate/acetate metabolites and may be useful in the evaluation of in vivo redox states.

28 October 2020 in Clinical Toxicology
Verified
Journal Article
Closed access
RWRobin Wijngaard
Robin Wijngaard
MPMarina Parra-Robert
Marina Parra-Robert
LMLourdes Marés
Lourdes Marés
AEAnna Escalante
Anna Escalante
ESEmilio Salgado
Emilio Salgado
MBMercè Brunet
Mercè Brunet
Amphetamine urine drug screening by immunoassay is prone to cross-react with other compounds leading to false positive results. Tetracaine is a local anesthetic drug used in the clinical setting as...

4 March 2024 in Clinical Toxicology
Verified
Journal Article
Closed access
GVGonzalo Verdú
Gonzalo Verdú
MGMaría Rodríguez García
María Rodríguez García
EMEva Martínez
Eva Martínez
LMLourdes Marés
Lourdes Marés
EMEdgar Martín
Edgar Martín
MPMarina Parra-Robert
Marina Parra-Robert

25 March 2025 in Adicciones
Verified
Journal Article
Open access
PDF file
Hugo Lopez-PelayoHugo Lopez-Pelayo
Hugo Lopez-Pelayo
NCNoel Cabrera
Noel Cabrera
ECElsa Caballeria
Elsa Caballeria
MPMaria Teresa Pons-Cabrera
Maria Teresa Pons-Cabrera
JMJuan Mena
Juan Mena
MBMercè Balcells-Olivero
Mercè Balcells-Olivero
En respuesta a la creciente popularidad de los productos derivados del cannabis con bajo contenido de THC y alto CBD, un estudio examinó si el consumo de estos productos podría resultar en pruebas positivas de THC en análisis de orina. Seis voluntarios consumieron productos con <0,2% de THC según las etiquetas, y las pruebas posteriores no detectaron el metabolito del THC en ninguna muestra. Esto sugiere que, al menos para esta partida específica, el consumo de CBD con bajo THC no es detectable en análisis de orina. Sin embargo, se enfatiza la necesidad de más estudios para explorar diferentes proveedores y entornos de venta, a fin de informar adecuadamente a los usuarios sobre los posibles riesgos asociados.